SYDNEY, AUSTRALIA: Alexium International Group Limited announced that Billy Blackburn has been appointed CEO and Managing Director of Alexium, effective 1 September 2022.

In this transition, Dr. Bob Brookins has been appointed Chief Technology Officer (CTO) and will remain an executive director on the Board. The Board is excited about the impact this appointment has on the Company’s skill sets and how the new organizational structure best leverages these.

Mr Blackburn has an accomplished background having founded a high-growth technology company specialising in high purity solvents, which was subsequently sold to Nova Molecular. Mr Blackburn was appointed Vice President, Business Development at Nova Molecular where he was responsible for substantial revenue growth that included securing major consumer healthcare contracts. More recently, Mr Blackburn has been the Vice President & Executive Manager with Giant Cement Holdings Inc., which is focused on Renewable Waste Processes.

Rosheen Garnon, Alexium Chair, said: “We are delighted to announce the appointment of Mr Blackburn given his 20 years of extensive commercial experience with high-growth technology companies.

This appointment comes at an important time in the Alexium growth cycle with the management team now heavily focused on commercialisation. With the number of commercial opportunities currently being pursued, it is crucial that we drive revenue growth and Mr Blackburn’s experience will complement our management team’s skill sets. In particular, this will enable Dr. Brookins, as Chief Technology Officer, to focus on product innovation and development, as well as customer product adoption.”

“I would like to acknowledge the tremendous job that Dr. Brookins has done over the past four years, effectively holding the roles of both CEO and CTO. We now have multiple technology platforms including BioCool, Eclipsys, Alexiflam and Alexiguard products. Our successful technology is a strong foundation for the company, and this has been developed by Dr. Brookins and our team. In order to focus on revenue growth, as well as continue our innovation programme and customer adoption of our technologies, it is important that we separate these two roles; it is a natural next step in our trajectory. Both Dr. Brookins and Mr Jason Lewis, the CFO, were involved in the selection process alongside the Board – this is a whole of team appointment.”